277 related articles for article (PubMed ID: 17459550)
1. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita S; Arita S
Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
[No Abstract] [Full Text] [Related]
3. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
[No Abstract] [Full Text] [Related]
4. A comparative study of milnacipran and paroxetine in outpatients with major depression.
Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
[TBL] [Abstract][Full Text] [Related]
5. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
Sakakibara R; Ito T; Uchiyama T; Awa Y; Yamaguchi C; Hattori T
Urol Int; 2008; 81(3):335-9. PubMed ID: 18931554
[TBL] [Abstract][Full Text] [Related]
6. Milnacipran and selective serotonin reuptake inhibitors in major depression.
Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
[TBL] [Abstract][Full Text] [Related]
7. Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine.
Munno D; Sterpone S; Fania S; Cappellin F; Mengozzi G; Saroldi M; Bechon E; Zullo G
Panminerva Med; 2013 Dec; 55(4):377-84. PubMed ID: 24434345
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients.
Başterzi AD; Yazici K; Aslan E; Delialioğlu N; Taşdelen B; Tot Acar S; Yazici A
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):281-5. PubMed ID: 19110026
[TBL] [Abstract][Full Text] [Related]
9. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
[TBL] [Abstract][Full Text] [Related]
10. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
Shinkai K; Yoshimura R; Ueda N; Okamoto K; Nakamura J
J Clin Psychopharmacol; 2004 Feb; 24(1):11-7. PubMed ID: 14709941
[TBL] [Abstract][Full Text] [Related]
11. Different serum BDNF levels in depression: results from BDNF studies in FYR Macedonia and Bulgaria.
Ristevska-Dimitrovska G; Shishkov R; Gerazova VP; Vujovik V; Stefanovski B; Novotni A; Marinov P; Filov I
Psychiatr Danub; 2013 Jun; 25(2):123-7. PubMed ID: 23793275
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
Kasper S; Pletan Y; Solles A; Tournoux A
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
[TBL] [Abstract][Full Text] [Related]
13. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
[TBL] [Abstract][Full Text] [Related]
14. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
Puech A; Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
[TBL] [Abstract][Full Text] [Related]
15. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients.
Yoshimura R; Kishi T; Suzuki A; Umene-Nakano W; Ikenouchi-Sugita A; Hori H; Otani K; Iwata N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1022-5. PubMed ID: 21338649
[TBL] [Abstract][Full Text] [Related]
16. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
Chang TT; Lêng CH; Wu JY; Lee SY; Wang YS; Chen YC; Lu RB
Chin J Physiol; 2008 Dec; 51(6):387-93. PubMed ID: 19280883
[TBL] [Abstract][Full Text] [Related]
17. Serum BDNF levels before treatment predict SSRI response in depression.
Wolkowitz OM; Wolf J; Shelly W; Rosser R; Burke HM; Lerner GK; Reus VI; Nelson JC; Epel ES; Mellon SH
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1623-30. PubMed ID: 21749907
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment.
Hellweg R; Ziegenhorn A; Heuser I; Deuschle M
Pharmacopsychiatry; 2008 Mar; 41(2):66-71. PubMed ID: 18311687
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of milnacipran: an overview.
Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
